Therapeutic strategies in extrinsic atopic dermatitis: Focus on inhibition of IL-4 as a new pharmacological approach

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Recent data about atopic dermatitis (AD) pathogenesis postulate that T cells and their related cytokines and chemokines are primarily responsible for the inflammatory responses.

Areas covered: AD, the primary complex disease associated with filaggrin deficiency, is characterized by cutaneous inflammation driven by type 2 helper T (TH2) cells. TH2-related molecules, such as IL-4, IL-13, dominate the immune infiltrate. Experimental evidences suggest that these cytokines may be considered attractive therapeutic targets in AD, particularly in extrinsic AD with IgE overproduction. Recently, a fully human monoclonal antibody directed against the IL-4 receptor α subunit blocking IL-4 and IL-13 signaling has been evaluated in Phase I and Phase II clinical trials in patients with moderate-to-severe AD with significant improvement in disease severity. Phase III trials are ongoing.

Expert opinion: Treatment of AD represents a therapeutic challenge. TH2 cytokine-targeted therapies represent promising treatment options that could improve the therapeutic armamentarium for AD. These therapies are likely to become future therapeutic options in AD, particularly in the extrinsic AD.

Original languageEnglish
Pages (from-to)87-96
Number of pages10
JournalExpert Opinion on Therapeutic Targets
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Atopic Dermatitis
Interleukin-4
Pharmacology
Therapeutics
Interleukin-13
Cytokines
Interleukin-4 Receptors
Th2 Cells
Phase II Clinical Trials
T-cells
Expert Testimony
Chemokines
Immunoglobulin E
Monoclonal Antibodies
Inflammation
T-Lymphocytes
Skin
Molecules

Keywords

  • Atopic dermatitis
  • Cytokines
  • IL-13
  • IL-4
  • Inhibition
  • Treatment

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine
  • Medicine(all)

Cite this

@article{82a7a87930ed4de6a5aaf27b332cd794,
title = "Therapeutic strategies in extrinsic atopic dermatitis: Focus on inhibition of IL-4 as a new pharmacological approach",
abstract = "Introduction: Recent data about atopic dermatitis (AD) pathogenesis postulate that T cells and their related cytokines and chemokines are primarily responsible for the inflammatory responses.Areas covered: AD, the primary complex disease associated with filaggrin deficiency, is characterized by cutaneous inflammation driven by type 2 helper T (TH2) cells. TH2-related molecules, such as IL-4, IL-13, dominate the immune infiltrate. Experimental evidences suggest that these cytokines may be considered attractive therapeutic targets in AD, particularly in extrinsic AD with IgE overproduction. Recently, a fully human monoclonal antibody directed against the IL-4 receptor α subunit blocking IL-4 and IL-13 signaling has been evaluated in Phase I and Phase II clinical trials in patients with moderate-to-severe AD with significant improvement in disease severity. Phase III trials are ongoing.Expert opinion: Treatment of AD represents a therapeutic challenge. TH2 cytokine-targeted therapies represent promising treatment options that could improve the therapeutic armamentarium for AD. These therapies are likely to become future therapeutic options in AD, particularly in the extrinsic AD.",
keywords = "Atopic dermatitis, Cytokines, IL-13, IL-4, Inhibition, Treatment",
author = "{Di Lernia}, Vito",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/14728222.2014.965682",
language = "English",
volume = "19",
pages = "87--96",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Therapeutic strategies in extrinsic atopic dermatitis

T2 - Focus on inhibition of IL-4 as a new pharmacological approach

AU - Di Lernia, Vito

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Recent data about atopic dermatitis (AD) pathogenesis postulate that T cells and their related cytokines and chemokines are primarily responsible for the inflammatory responses.Areas covered: AD, the primary complex disease associated with filaggrin deficiency, is characterized by cutaneous inflammation driven by type 2 helper T (TH2) cells. TH2-related molecules, such as IL-4, IL-13, dominate the immune infiltrate. Experimental evidences suggest that these cytokines may be considered attractive therapeutic targets in AD, particularly in extrinsic AD with IgE overproduction. Recently, a fully human monoclonal antibody directed against the IL-4 receptor α subunit blocking IL-4 and IL-13 signaling has been evaluated in Phase I and Phase II clinical trials in patients with moderate-to-severe AD with significant improvement in disease severity. Phase III trials are ongoing.Expert opinion: Treatment of AD represents a therapeutic challenge. TH2 cytokine-targeted therapies represent promising treatment options that could improve the therapeutic armamentarium for AD. These therapies are likely to become future therapeutic options in AD, particularly in the extrinsic AD.

AB - Introduction: Recent data about atopic dermatitis (AD) pathogenesis postulate that T cells and their related cytokines and chemokines are primarily responsible for the inflammatory responses.Areas covered: AD, the primary complex disease associated with filaggrin deficiency, is characterized by cutaneous inflammation driven by type 2 helper T (TH2) cells. TH2-related molecules, such as IL-4, IL-13, dominate the immune infiltrate. Experimental evidences suggest that these cytokines may be considered attractive therapeutic targets in AD, particularly in extrinsic AD with IgE overproduction. Recently, a fully human monoclonal antibody directed against the IL-4 receptor α subunit blocking IL-4 and IL-13 signaling has been evaluated in Phase I and Phase II clinical trials in patients with moderate-to-severe AD with significant improvement in disease severity. Phase III trials are ongoing.Expert opinion: Treatment of AD represents a therapeutic challenge. TH2 cytokine-targeted therapies represent promising treatment options that could improve the therapeutic armamentarium for AD. These therapies are likely to become future therapeutic options in AD, particularly in the extrinsic AD.

KW - Atopic dermatitis

KW - Cytokines

KW - IL-13

KW - IL-4

KW - Inhibition

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84918564629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918564629&partnerID=8YFLogxK

U2 - 10.1517/14728222.2014.965682

DO - 10.1517/14728222.2014.965682

M3 - Article

C2 - 25283256

AN - SCOPUS:84918564629

VL - 19

SP - 87

EP - 96

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -